Biotechnology
Technology
Health

Catalyst Pharmaceuticals

$4.07
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.54 (15.52%) Today
+$0.05 (1.24%) After Hours

Why Robinhood?

You can buy or sell CPRX and other stocks, options, ETFs, and crypto commission-free!

About

Catalyst Pharmaceuticals, Inc. Common Stock, also called Catalyst Pharmaceuticals, is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasmsThe company was founded Huckel E. Read More Hubert in January 2002 and is headquartered in Coral Gables, FL.

Employees
51
Headquarters
Coral Gables, Florida
Founded
2002
Market Cap
413.01M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.11M
High Today
$4.09
Low Today
$3.57
Open Price
$3.57
Volume
2.13M
52 Week High
$4.09
52 Week Low
$1.85

Collections

Biotechnology
Technology
Health
Top Movers
Pharmaceutical
Biopharmaceutical
US
North America

News

The Motley FoolMar 19

Why Catalyst Pharmaceuticals Stock Is Popping Today

What happened Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX), a maker of drugs for rare diseases, rose by as much as 19.1% on more than three times the average daily volume today. What sparked this rally? Catalyst's shares are jumping in response to the company's fourth-quarter and full-year earnings report released after the bell Monday. The news is that Firdapse, the company's newly approved medicine for patients with the autoimmune disease Lambert-Eaton Myasthenic Syndrome (LEMS), is off to a strong ...

3,880
Yahoo FinanceMar 19

Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse

Catalyst Pharmaceuticals, Inc. CPRX reported a loss of 14 cents per share in the fourth quarter of 2018, wider than the Zacks Consensus Estimate of a loss of 12 cents and the year-ago loss of 6 cents. During the fourth quarter of 2018, Catalyst had revenues of $0.5 million from its collaboration with Endo International Plc. ENDP to market the generic version of Sabril tablets. On Dec 18, 2018, Catalyst signed a definitive agreement with Endo International PLC’s subsidiary, Endo Ventures Limited (“Endo”), ...

353
The Motley FoolMar 19

Catalyst Pharmaceuticals Inc (CPRX) Q4 2018 Earnings Conference Call Transcript

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Q4 2018 Earnings Conference Call , 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Greetings and welcome to the Catalyst Pharmaceuticals' Fourth Quarter and Year End 2018 Financial Results Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded. I woul...

188

Earnings

-$0.14
-$0.11
-$0.08
-$0.05
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.12 per share
Actual
-$0.14 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.